Mechanisms Of Local And Systemic Inflammation In Chronic Obstructive Pulmonary Disease With Comorbid Hypertension And Obesity
Ganna Stupnytska, Oleksandr Fediv
Index Terms: chronic obstructive pulmonary disease, hypertension, obesity, inflammation, exhaled breath condensate, blood.
Abstract: Today chronic obstructive pulmonary disease (COPD) is considered not only as a disease with changes in the bronchial tree and lungs, but also as a systemic inflammatory syndrome with systemic effects and the presence of comorbidities. The objectives of this study were to evaluate the lipid peroxidation, antioxidant system and proteolysis intensity in the blood and exhaled breath condensate (EBC), as well as local balance between pro- and anti-inflammatory cytokines in COPD patients’ with hypertension and obesity. The study included 25 healthy subjects and 50 patients with COPD without hypertension and with comorbid hypertension and obesity (36 patients). General tripsin-like proteinase (TLP) activity was determined by Kunits method, neutral proteolytic activity of citrate blood plasma and EBC – by azoalbumin, azocasein and azocol lysis. Superoxyddismutase (SOD) and catalase (Ct) activity, malone dialdehyde (MDA) level, HS-group content in the blood and EBC were also examined. The concentration of cytokines (TNFα, IL-1β, TGF- β1, IFN γ) were marked with ELISA method. Patients with COPD and comorbid hypertension and obesity showed more elevation of TNFα, IL-1β, TGF- β1, in EBC, local and systemic higher MDA index, decrease of Ct and SOD activity in EBC and increased Ct activity in blood, activation of neutral proteolytic systems and acid TLP, reduced collagenolysis intensity. The course of COPD with hypertension and obesity was characterized by more intensification of inflammatory process on the level of the bronchial tree and with more systemic inflammatory response.
 Luppi F, Franco F, Beghe B: Treatment of Chronic Obstructive Pulmonary Disease and Its Comorbidities. Proc Am Thorac Soc 2008, 5, 848–856.
 Bolton CE, Cockcroft JR: Lung function and cardiovascular risk: a stiff challenge? Am J Hypertension 2010, 23, 584–588.
 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease, 2011. http://www.goldcopd.org/Guidelines/guidelines-resources.html.
 Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33, 1165–1185.
 Nussbaumer-Ochsner Y, Rabe KF: Systemic manifestations of COPD. Chest 2011, 139, 165-173.
 Grob NM, Aytekin M, Dweik RA: Biomarkers in exhaled breath condensate: rewiew of collection, processing and analysis. J Breath Res 2008, 2, 1-33.
 Bartoli MI, Novelli F, Costa F: Malondialdehyde in exhaled breath condenste as a marker of oxidative stress in different pulmonary diseases. Mediators of inflammation 2011, 1-7.
 Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem Biophys 2005, 43, 167–188.
 Borrill ZL, Roy K, Singh D: Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008, 32, 472-486.
 Louheinen N, Myllarniemi M: Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease. International J of COPD 2008, 3(4), 585-603.
 Ochs-Balcom HM, Grant BJB, Muti P: Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. Eur J Clin Nutr 2006; 60: 991–999.
 MacCallum PK: Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2005, 2(1), 34-43.
 Magnussen H, Watz H: Systemic inflammation in chronic obstructive pulmonary disease and asthma: relation with comorbidities. Proc Am Thorac Soc 2009, 6, P.648-651.
 Ashitani J, Mukae H, Arimura Y, Matsukura S: Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002, 41(3), 181-185.